COOPER COMPANIES, INC. 8-K

What Happened

• On June 4, 2026, The Cooper Companies, Inc. filed an 8-K furnishing a press release reporting results for its fiscal second quarter ended April 30, 2026. The same filing discloses that the company recorded a net $271.6 million charge related to settlements and accruals for claims arising from a December 2023 voluntary recall by its CooperSurgical unit of three lots of LifeGlobal embryo culture media.
• Management said developments from mid‑March 2026 — including faster litigation schedules, more claimant information, higher projected defense and expert costs, and updated damage valuations — prompted a reassessment of exposure and led to settlement agreements covering over 95% of claimants.

Key Details

• Date of filing/press release: June 4, 2026; fiscal quarter ended April 30, 2026.
• Net impact recorded to results: $271.6 million (comprised of $324.1M accrued litigation liabilities less $52.5M expected insurance recoveries). Amount recorded in Selling, General & Administrative expenses.
• Claims/litigation status: more than 140 lawsuits (including three un‑certified putative class actions) and over 1,500 proffered claimants; settlements cover >95% of claimants.
• Timing: Company expects the majority of payments related to these settlements to be made during fiscal 2026.

Why It Matters

• The $271.6M net charge is a material, one‑time expense that will reduce reported profitability for the quarter/year and is recorded in SG&A rather than as an operating or insurance gain.
• Insurance is expected to cover part of the cost ($52.5M recoverable), but management concluded potential exposure could exceed available insurance, prompting the accrual and settlements.
• Investors should note the operational context (CooperSurgical recall) and monitor upcoming periodic filings for any further updates on cash outflows, insurance recoveries, litigation developments, and the company’s quarterly financial results.